推薦產品
生物源
mouse
品質等級
抗體表格
purified immunoglobulin
抗體產品種類
primary antibodies
無性繁殖
A2b1, monoclonal
物種活性
human, rat, mouse
製造商／商標名
Chemicon®
技術
immunocytochemistry: suitable
immunohistochemistry: suitable
immunoprecipitation (IP): suitable
western blot: suitable
同型
IgG1
適合性
not suitable for immunohistochemistry (Paraffin)
NCBI登錄號
UniProt登錄號
運輸包裝
wet ice
目標翻譯後修改
unmodified
基因資訊
human ... PTEN(5728) , TEP1(7011)
特異性
Specifically recognizes PTEN*, a tumor suppressor protein located on human chromosome 10 (Steck, ′97; Li, ′97; Rhei, ′97) that is often mutated in various types of advanced cancers (Rhei, ′97). The PTEN protein exhibits protein phosphatase activity (Myers, ′97) and can suppress the growth of glioma cells (Furnari, ′97). The antibody recognizes human and mouse PTEN and is specific for the C-terminus. Other species not tested. Reactivity with human fibroblasts, breast epithelial and lung cancer cell lines has been confirmed by western blot, and antibody specificity has been confirmed by peptide blocking studies.
*PTEN is covered under U.S. patents 6,262,242, 6,482,795 and U.S. patent application 10/299,003.
*PTEN is covered under U.S. patents 6,262,242, 6,482,795 and U.S. patent application 10/299,003.
免疫原
Anti-PTEN was generated by immunization with a 10 amino acid peptide corresponding to amino acids 387-400 near the C-terminus of human PTEN.
Epitope: C-terminus
應用
Anti-PTEN Antibody, C-terminus, clone A2b1 is an antibody against PTEN for use in IC, IH, IP & WB.
Research Category
Signaling
Signaling
Research Sub Category
PI3K, Akt, & mTOR Signaling
PI3K, Akt, & mTOR Signaling
Western blot 1:100 (55 kDa)
Immunocytochemistry
Immunohistochemistry: 1:20 to 1:50 for acetone-fixed, fresh frozen tissue. Not effective for paraffin sections.
Immunoprecipitation 1:10 to 1:20
Protocol for immunohistochemistry of frozen tissue sections on glass slides.
1. Fix sections for 5 minutes with cold acetone.
2. Air dry
3. Wash sections with PBS
4. Add blocking solution (horse serum) for 20 minutes
5. Add diluted PTEN antibody and incubate for 1 hour at room temperature.
6. Wash with PBS
7. Add biotinylated secondary antibody (horse anti-mouse, or equivalent).
8. Incubate for 30 minutes at room temperature.
9. Wash with PBS
10. Detect with ABC (Avidin-Peroxidase-Complex) or equivalent.
11. Wash with PBS
12. Develop with DAB substrate.
13. Hematoxylin dye may be used as a counterstain for visualizing nuclei.Breast tumor tissue gives good staining. Prostate tissue does not stain.Optimal working dilutions must be determined by end user.
Immunocytochemistry
Immunohistochemistry: 1:20 to 1:50 for acetone-fixed, fresh frozen tissue. Not effective for paraffin sections.
Immunoprecipitation 1:10 to 1:20
Protocol for immunohistochemistry of frozen tissue sections on glass slides.
1. Fix sections for 5 minutes with cold acetone.
2. Air dry
3. Wash sections with PBS
4. Add blocking solution (horse serum) for 20 minutes
5. Add diluted PTEN antibody and incubate for 1 hour at room temperature.
6. Wash with PBS
7. Add biotinylated secondary antibody (horse anti-mouse, or equivalent).
8. Incubate for 30 minutes at room temperature.
9. Wash with PBS
10. Detect with ABC (Avidin-Peroxidase-Complex) or equivalent.
11. Wash with PBS
12. Develop with DAB substrate.
13. Hematoxylin dye may be used as a counterstain for visualizing nuclei.Breast tumor tissue gives good staining. Prostate tissue does not stain.Optimal working dilutions must be determined by end user.
標靶描述
55 kDa
聯結
Replaces: 04-409
外觀
Protein A purified
Format: Purified
Protein A Purified mouse immunoglobulin in 20 mM sodium phosphate, 250 mM NaCl, pH. 7.6, with 0.1% sodium azide as a preservative.
儲存和穩定性
Maintain for 1 year at 2–8°C from date of shipment. Aliquot to avoid repeated freezing and thawing. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
分析報告
Control
Breast tumor tissue
Purified active kinase is Catalogue Number 14-488
Breast tumor tissue
Purified active kinase is Catalogue Number 14-488
其他說明
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
法律資訊
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
免責聲明
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
未找到適合的產品？
試用我們的產品選擇工具.
儲存類別代碼
10 - Combustible liquids
水污染物質分類（WGK）
WGK 2
閃點（°F）
Not applicable
閃點（°C）
Not applicable
分析證明 (COA)
輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。
Delira Robbins et al.
FEBS letters, 586(23), 4108-4113 (2012-11-06)
Our recent studies suggest a unique role of p53 during the early stage of cancer development. However, how p53 activation is regulated during TPA treatment remains elusive. We used murine skin epidermal JB6 promotion-sensitive (P+) and promotion resistant (P-) cells
Carsten B Schmidt-Weber et al.
European journal of immunology, 32(4), 1196-1204 (2002-04-05)
The phosphatidylinositol phosphatase gene PTEN is a dual specific phosphatase acting on phospho amino acids but also on three phosphorylated inositol phospholipids. Present results demonstrate that PTEN is inducible by costimulatory signals in human CD4(+) T cells. PTEN expression was
Janice B B Lam et al.
PloS one, 4(3), e4968-e4968 (2009-03-26)
Adiponectin is an adipokine possessing beneficial effects on obesity-related medical complications. A negative association of adiponectin levels with breast cancer development has been demonstrated. However, the precise role of adiponectin deficiency in mammary carcinogenesis remains elusive. In the present study
Danyu Cui et al.
Molecular medicine reports, 16(5), 7813-7820 (2017-09-26)
A number of short noncoding microRNAs (miRs) have been demonstrated to be highly expressed in many kidney diseases such as renal cancer and lupus nephritis (LN); however, these results have not been extensively investigated. The aim of the present study
Maria C Pazos et al.
Journal of cellular physiology, 233(8), 5949-5961 (2017-12-22)
Ovarian cancer is the fifth leading cause of cancer-related deaths in women. In the past 20 years, the canonical types of drugs used to treat ovarian cancer have not been replaced and the survival rates have not changed. These facts
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務